Ranbaxy's 'Operation Orchid'  |  |  | | Orchid's top management is weighing different options to ward off any takeover bid by Ranbaxy. Orchid's promoter is garnering support, including alliances with other pharma companies, to keep out Ranbaxy, after Solrex's stake hike in Orchid. Though Ranbaxy has denied any hostile takeover bid, the status could change over the next few days. | | | |
| |  | Ball in Orchid's court
Ranbaxy made it clear that it is interested in Orchid, but does not want to be hostile in its approach to acquire the Chennai-based pharma company. | | ................................................................................................................................................................. | | |  | Appetising pill
With Ranbaxy-backed financial investment firm Solrex's raising its stake in Orchid, the Krebs Biochemicals, and Jupiter Biosciences and Zenotech Lab counters are witnessing hectic activity. | | ................................................................................................................................................................. | 'In a safe position'
The promoters of Orchid Pharmaceuticals have been
aggressively raising funds to build capacities. Talks are on
with foreign portfolio funds that are willing to
invest in Orchid. |
|
Orchid scrips
active
The
spike in share price fuelled curiosity on whether Orchid had
agreed to a pact with Ranbaxy or Orchid’s promoter had
managed to
bring in funds.
|
| | ................................................................................................................................................................. | | ................................................................................................................................................................. | | |
